Fosun Pharma has contributed to a $250m series D round for medical device maker Butterfly Network, valuing the company at $1.25bn.

Novo has co-led a series B round together with Omega Funds for Morphic Therapeutic, based on research by Harvard professor Timothy Springer.

The Astra Zeneca antibiotic development spin off has floated in an initial public offering in which Novo bought more than $16m in shares.

CUNY-born digital olfaction technology developer MouSensor will receive funding and expertise from nanoelectronics institute Imec's investment fund.

University of Iowa's medical diagnostics spinout IDx has collected $33m from investors including Optum, bringing the company’s total to $48m.

State-wide innovation hubs under the banner of Michigan Translational Research and Commercialization will receive money from the Michigan Strategic Fund.

The EEG system developer raised the series B funding from investors including UCB and LivaNova and will use it commercialise its lead device.

Alexion will pay $400m upfront for Baxalta-backed Syntimmune, with up to an additional $800m on offer if the autoimmune disease drug developer hits all its milestones.

PharmEasy took its total funding past the $100m mark, six months after collecting some $30m from investors including Manipal Education and Medical Group.

Novo has co-led the series B round together with Omega Funds, adding to a $51.5m series A co-led by GlaxoSmithKline and Pfizer in 2016.